Data on Cancer Reported by Researchers at H. Lee Moffitt Cancer Center and Research Institute (15 Years of Patient-reported Outcomes In Clinical Trials Leading To Gu Cancer Drug Approvals: a Systematic Review On the Quality of Data Reporting...).

A recent study conducted at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, Florida evaluated the reporting methods of patient-reported outcomes (PRO) data in FDA-approved drugs for genitourinary (GU) malignancies. The study found that while PRO data was published for 27 trials, only 85% of these publications focused solely on PRO data. The study also highlighted the need for improvement in the quality of design and conduct of PRO endpoints in future trials, as well as the accelerated publication of PRO endpoints. The researchers concluded that these improvements are essential for facilitating the interpretation and application of PRO study findings in patient care. [Extracted from the article]